TherapeuticsMD, Inc. (TXMD) Short Interest Update

TherapeuticsMD, Inc. (NASDAQ:TXMD) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 55,856,043 shares, a growth of 35.8% from the October 13th total of 41,131,584 shares. Currently, 32.1% of the company’s shares are short sold. Based on an average daily volume of 2,240,090 shares, the short-interest ratio is currently 24.9 days.

TherapeuticsMD (NASDAQ TXMD) opened at $5.97 on Thursday. TherapeuticsMD has a 12-month low of $3.50 and a 12-month high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The business had revenue of $4.42 million for the quarter, compared to the consensus estimate of $5.36 million. During the same period in the prior year, the firm posted ($0.13) earnings per share. The business’s quarterly revenue was down 19.7% on a year-over-year basis. research analysts anticipate that TherapeuticsMD will post -0.37 EPS for the current year.

A number of research firms have weighed in on TXMD. Cowen and Company restated an “outperform” rating and set a $16.00 target price (up previously from $13.00) on shares of TherapeuticsMD in a report on Monday, November 6th. BidaskClub upgraded TherapeuticsMD from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 25th. Oppenheimer Holdings, Inc. set a $10.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a report on Monday, October 16th. Jefferies Group LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of TherapeuticsMD in a research report on Tuesday, September 26th. Finally, Deutsche Bank AG reaffirmed a “buy” rating and set a $10.00 price target on shares of TherapeuticsMD in a research report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $14.72.

In other news, Director Tommy G. Thompson purchased 5,000 shares of the stock in a transaction that occurred on Wednesday, August 30th. The stock was purchased at an average price of $5.99 per share, for a total transaction of $29,950.00. Following the completion of the acquisition, the director now owns 3,555 shares of the company’s stock, valued at $21,294.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 23.92% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bamco Inc. NY increased its position in shares of TherapeuticsMD by 8.2% in the 3rd quarter. Bamco Inc. NY now owns 920,000 shares of the company’s stock valued at $4,867,000 after acquiring an additional 70,000 shares during the period. Alyeska Investment Group L.P. acquired a new position in shares of TherapeuticsMD in the 3rd quarter valued at $2,812,000. Wells Fargo & Company MN increased its position in shares of TherapeuticsMD by 13.6% in the 3rd quarter. Wells Fargo & Company MN now owns 217,820 shares of the company’s stock valued at $1,153,000 after acquiring an additional 26,007 shares during the period. 1492 Capital Management LLC increased its position in shares of TherapeuticsMD by 86.4% in the 3rd quarter. 1492 Capital Management LLC now owns 390,702 shares of the company’s stock valued at $2,067,000 after acquiring an additional 181,115 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of TherapeuticsMD by 40.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,027,855 shares of the company’s stock valued at $112,783,000 after acquiring an additional 6,340,346 shares during the period. 72.54% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This story was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/11/16/therapeuticsmd-inc-txmd-short-interest-update.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply